Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide plus CC-115 in CRPC
NCT02833883Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2016
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cc-115 in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Safety and Tolerability at 1 year. Started Jul 2016; status: completed.
02
Drugs
cc-115
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02833883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833883.